replic
caus
desquam
epitheli
cell
induc
chang
region
lymphat
tissu
includ
hypertrophi
activ
prolif
germin
center
result
lymphadenopathi
intussuscept
particularli
children
innat
adapt
immun
respons
critic
control
adenoviru
replic
lymphocyt
play
particularli
import
role
control
clearanc
replic
adenoviru
human
deficit
associ
progress
dissemin
immunosuppress
patient
groupand
typespecif
neutral
nonneutr
antibodi
play
signific
role
limit
infect
prevent
vaccin
care
attent
infect
control
practic
exist
prevent
strategi
date
vaccin
avail
member
militari
usa
year
old
contact
droplet
precaut
recommend
prevent
healthcareassoci
institut
outbreak
adenoviru
infect
includ
epidem
keratoconjunct
likewis
care
attent
hand
hygien
standard
steril
medic
equip
come
contact
patient
proven
suspect
adenoviru
infect
essenti
diagnosi
adenoviru
depend
isol
viru
infect
tissu
either
histopatholog
evid
local
replic
clinic
symptom
consist
infect
confirm
infect
confus
latent
infect
tissu
tonsil
intermitt
sometim
prolong
shed
viru
throat
stool
month
year
primari
infect
direct
detect
adenoviru
clinic
isol
gener
achiev
cultur
direct
fluoresc
antigen
detect
polymeras
chain
reaction
pcr
adenoviru
readili
grown
hek
cell
line
see
figur
typic
cytopath
effect
fluoresc
antibodi
use
confirm
infect
molecular
novel
strain
adenoviru
recent
identifi
caus
clinic
signific
sometim
sever
infect
otherwis
healthi
adult
children
novel
coronaviru
merscov
emerg
caus
sever
respiratori
infect
arabian
peninsula
short
inhibitori
rna
shown
promis
manag
respiratori
syncyti
viru
rsv
lung
transplant
recipi
yet
approv
treatment
rsv
human
rhinovirus
common
caus
common
cold
also
common
trigger
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
human
metapneumoviru
signific
caus
diseas
young
children
human
bocaviru
newli
discov
respiratori
pathogen
although
coinfect
virus
often
document
human
adenovirus
hadv
member
adenovirida
famili
envelop
doublestrand
dna
dsdna
virus
hadv
divid
serotyp
seven
speci
b
c
e
f
g
see
tabl
base
serum
neutral
hemagglutin
epitop
genom
sequenc
function
oncogen
properti
patholog
human
epidemiolog
adenovirus
caus
rang
infect
mild
selflimit
respiratori
viral
infect
conjunct
diarrhea
sever
dissemin
diseas
adenovirus
worldwid
distribut
infect
occur
throughout
year
without
signific
season
variabl
infect
occur
sporad
event
although
local
region
epidem
describ
infect
common
children
gener
less
year
age
children
diarrhea
infect
adenoviru
typic
adv
recent
sever
often
fatal
outbreak
adv
occur
start
usa
adv
adv
recombin
viru
recogn
caus
signific
outbreak
diseas
china
adenoviru
lead
caus
respiratori
viral
infect
among
militari
recruit
unfortun
mani
respiratori
viru
multiplex
panel
low
yield
adenoviru
patient
clinic
infect
especi
true
respiratori
sampl
collect
respiratori
tract
primari
site
infect
quantit
pcr
assay
use
predict
progress
dissemin
diseas
pediatr
lesser
extent
adult
stem
cell
transplant
hsct
recipi
assess
respons
antivir
therapi
clinic
manifest
adenoviru
infect
associ
wide
rang
clinic
manifest
includ
respiratori
tract
ocular
gastrointestin
tract
genitourinari
tract
central
nervou
system
cn
infect
among
other
dissemin
infect
also
occur
typic
immunosuppress
host
pharyng
laryngotrach
bronchiti
pneumonia
describ
typic
symptom
includ
nasal
congest
coryza
cough
often
accompani
system
manifest
gener
malais
fever
chill
myalgia
headach
abdomin
pain
exud
tonsil
cervic
adenopathi
often
frequent
observ
conjunct
accompani
sign
symptom
diseas
design
pharyngoconjunctiv
fever
rare
pertussislik
syndrom
describ
typic
caus
adv
pneumonia
usual
diffus
bilater
interstiti
infiltr
describ
may
particularli
sever
adv
recent
outbreak
sever
adv
result
signific
morbid
mortal
patient
individu
present
fever
cough
requir
hospit
supplement
oxygen
critic
care
minor
receiv
vasopressor
die
older
age
chronic
underli
condit
low
absolut
lymphocyt
count
elev
creatinin
level
associ
sever
ill
two
common
manifest
ocular
adenoviru
infect
pharyngoconjunctiv
fever
epidem
keratoconjunct
ekc
pharyngoconjunctiv
fever
typic
milder
form
acut
follicular
conjunct
accompani
febril
pharyng
cervic
aden
symptom
typic
resolv
without
sequela
treatment
indic
epidem
keratoconjunct
ekc
seriou
diseas
much
longer
time
recoveri
follow
day
incub
follicular
conjunct
edema
eyelid
pain
lacrim
photophobia
preauricular
lymph
node
hypertrophi
rare
selflimit
pain
corneal
opac
develop
epidem
keratoconjunct
typic
caus
adenoviru
type
first
seen
shipyard
worker
whose
eye
slightli
injur
chip
rust
paint
although
patient
may
experi
signific
pain
blurri
vision
ekc
typic
resolv
without
perman
corneal
damag
week
pediatr
case
diarrhea
caus
group
f
adv
higher
rate
adenovirusinduc
diarrhea
describ
season
outbreak
lowand
middleincom
area
world
adenovirusassoci
diarrhea
typic
prolong
last
day
outbreak
close
commun
clinic
set
describ
mesenter
aden
common
clinic
mimic
append
result
intussuscept
young
children
adenoviru
infect
may
masquerad
reject
small
bowel
transplant
recipi
rule
biopsi
patient
hemorrhag
cystiti
typic
present
microscop
macroscop
hematuria
pain
cramp
bladder
associ
adv
adenoviru
tubulointerstiti
nephriti
occur
mostli
commonli
kidney
transplant
recipi
present
transient
elev
serum
creatinin
hemorrhag
cystiti
rare
manifest
includ
mening
enceph
myocard
dilat
myocardiopathi
addit
echogen
liver
lesion
without
hydrop
neural
defect
fetus
also
describ
adenoviru
diseas
immunocompromis
adult
children
rang
asymptomat
shed
progress
often
fatal
dissemin
diseas
risk
factor
adenovir
infect
hsct
popul
includ
allogen
donor
vs
autolog
donor
pediatr
age
group
vs
adult
celldeplet
graft
vs
use
alemtuzumab
cord
blood
donor
patient
acut
graftversushost
diseas
kong
vietnam
singapor
taiwan
canada
matter
week
end
epidem
countri
affect
result
confirm
infect
death
primari
mode
transmiss
via
respiratori
droplet
basic
reproduct
number
sar
rang
howev
frequent
nosocomi
outbreak
superspread
event
greatli
exacerb
transmiss
notabl
sar
victim
healthcar
worker
diseas
attack
rate
hospit
viral
kinet
peak
time
clinic
deterior
applic
aerosolgener
procedur
devic
eg
intub
resuscit
oxygen
nebul
therapi
bilevel
posit
airway
pressur
bipap
overcrowded
lack
proper
isol
facil
hospit
explan
commun
superspread
event
occur
privat
hous
estat
hong
kong
involv
resid
dri
ushap
bathroom
floor
drain
backflow
contamin
sewag
sar
patient
diarrhea
coupl
toilet
exhaust
fan
might
creat
infecti
aerosol
rose
warm
air
along
build
airshaft
dispers
wind
flow
caus
longrang
transmiss
nearbi
build
evid
suggest
sar
could
opportunist
airborn
first
case
merscov
infect
emerg
june
saudi
arabia
qatar
may
total
confirm
infect
death
report
middl
eastern
countri
saudi
arabia
qatar
jordan
unit
arab
emir
predominantli
affect
import
case
uk
netherland
usa
asia
report
largest
outbreak
outsid
middl
east
occur
south
korea
involv
multipl
hospit
individu
caus
death
although
zoonot
transmiss
implic
major
infect
case
report
histori
direct
anim
contact
epidemiolog
investig
suggest
sporad
transmiss
diseas
multipl
introduct
atrisk
popul
found
occup
exposur
camel
eg
shepherd
slaughterhous
work
associ
time
higher
risk
seroconvers
gener
popul
also
larg
number
younger
year
infect
individu
develop
mild
symptom
might
exist
serv
sourc
infect
without
direct
anim
contact
secondari
transmiss
household
uncommon
occur
case
cluster
transmiss
typic
highli
effici
hospit
set
via
infecti
dropletsaerosol
lead
frequent
occurr
nosocomi
outbreak
case
sar
pathogen
cellular
receptor
aminopeptidas
n
apn
cellular
receptor
sialic
acid
cell
surfac
like
sarscov
bind
human
preexist
immun
sarscov
merscov
novel
virus
abil
evad
innat
host
defens
eg
type
interferon
respons
relat
mechan
replic
effici
host
tissu
respiratori
intestin
tract
cell
kidney
cell
also
merscov
addit
lytic
cell
damag
uncontrol
replic
sarscov
lead
unab
inflammatori
cytokin
activ
commonli
known
cytokin
storm
implic
develop
progress
pneumon
diffus
alveolar
damag
acut
respiratori
distress
syndrom
ard
hemophagocyt
syndrom
high
viral
load
slow
viral
clearanc
due
ineffici
host
respons
associ
progress
diseas
fatal
outcom
pathogenesi
data
merscov
limit
macaqu
model
shown
activ
viral
replic
lung
tissu
caus
localizedtowidespread
lesion
clinic
ill
abat
week
ill
infect
marmoset
develop
sever
interstiti
pneumonia
similar
human
case
neutrophil
macrophag
infiltr
alveolar
oedema
note
gvhd
although
dissemin
diseas
effect
hsct
recipi
associ
signific
risk
mortal
incid
among
solid
organ
transplant
recipi
popul
highest
small
bowel
liver
transplant
recipi
pediatr
transplant
recipi
patient
receiv
antilymphocyt
antibodi
patient
donorpositiverecipientneg
adenoviru
statu
asymptomat
adenoviru
dnaemia
common
among
solid
organ
transplant
recipi
gener
associ
progress
symptomat
diseas
manag
although
antivir
specif
approv
treatment
adenoviru
sever
vitro
vivo
experiment
data
support
use
singl
agent
consist
effect
case
exist
data
suggest
cidofovir
lipid
ester
analog
brincidofovir
effect
manag
adenoviru
infect
adenovirusand
multivirusspecif
cell
emerg
potenti
therapi
safe
use
low
frequenc
de
novo
graftversushost
diseas
complet
partial
respons
adenoviru
infect
serial
measur
quantit
viral
load
predict
respons
therapeut
intervent
coronavirus
larg
lipidenvelop
positivesens
singlestrand
rna
virus
human
coronavirus
eg
hcov
commonli
caus
mild
upper
respiratori
tract
infect
although
occasion
result
sever
diseas
immunocompromis
individu
howev
two
novel
human
coronavirus
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
recent
identifi
middl
east
respiratori
syndromeassoci
coronaviru
merscov
may
caus
seriou
viral
pneumon
lead
hospit
death
viral
genom
analys
reveal
sarscov
belong
group
b
merscov
belong
group
c
betacoronaviru
respect
close
relat
coronaviru
strain
found
bat
intermedi
mammalian
host
civet
cat
implic
sarscov
adapt
human
transmiss
emerg
evid
viru
antibodi
detect
suggest
dromedari
camel
like
host
merscov
surfac
spike
glycoprotein
sprotein
coronavirus
key
virul
factor
attach
viru
host
cell
determin
host
rang
tissu
tropism
target
neutral
antibodi
sarscov
use
human
angiotensinconvert
enzym
aceii
primari
cellular
receptor
human
cellular
ctype
lectin
dclsign
may
altern
merscov
shown
bind
dipeptidyl
peptidas
also
call
interspeciesconserv
protein
found
surfac
sever
cell
type
includ
noncili
cell
human
airway
explain
broaden
host
rang
abil
caus
crossspeci
zoonot
transmiss
hcov
ubiquit
among
human
major
caus
respiratori
diseas
account
common
cold
serolog
studi
also
suggest
onehalf
infect
coronavirus
asymptomat
two
newlydescrib
coronavirus
also
common
caus
typic
mild
selflimit
cold
sever
clinic
diseas
describ
young
children
elderli
immunocompromis
patient
sarscov
emerg
southern
china
guangdong
provinc
late
first
victim
involv
live
anim
trade
food
handler
restaur
serv
exot
anim
meat
intern
air
travel
diseas
quickli
spread
hong
efficaci
question
ribavirin
though
shown
activ
vitro
seem
provid
clinic
benefit
hiv
proteaseinhibitor
lopinavirritonavir
vitro
activ
sarscov
report
caus
viral
load
reduct
fewer
ard
death
patient
howev
studi
uncontrol
anoth
studi
report
patient
receiv
convalescentplasma
recov
individu
contain
neutral
antibodi
better
clinic
outcom
surviv
vs
discharg
rate
vs
subsequ
vitro
anim
ferret
hamster
macaqu
studi
shown
monoclon
antibodi
target
sprotein
may
provid
neutral
activ
sarscov
result
viral
load
reduct
resolut
lung
lesion
vitro
anim
mice
macaqu
studi
show
type
interferon
given
prophylact
shortli
exposur
may
protect
sar
small
clinic
studi
interferonalpha
given
within
day
associ
lower
rate
intub
vs
death
vs
merscov
avail
data
shown
type
type
iii
interferon
activ
vitro
combin
ribavirin
given
hour
infect
appear
reduc
lung
injuri
macaqu
model
clinic
data
limit
among
patient
receiv
treatment
consist
result
observ
one
retrospect
studi
surviv
versu
day
reach
statist
signific
anim
model
suggest
potenti
benefit
antivir
agent
antibodybas
therapi
clinic
data
publish
date
system
corticosteroid
treatment
highli
controversi
favor
clinic
radiolog
respons
report
control
data
lack
random
placebocontrol
studi
perform
sar
outbreak
earli
corticosteroid
treatment
within
first
day
delay
viral
clearanc
later
systemat
review
ded
corticosteroid
associ
definit
benefit
like
harm
eg
metabol
side
effect
bacteri
fungal
superinfect
avascular
osteonecrosi
acut
psychosi
current
corticosteroid
therapi
recommend
sarscov
merscov
avian
influenza
infect
perhap
except
case
refractori
septic
shock
adren
insuffici
given
low
dose
eg
hydrocortison
mg
respiratori
syncyti
viru
respiratori
syncyti
viru
rsv
envelop
singlestrand
rna
paramyxoviru
includ
two
major
group
b
consist
genotyp
rsv
genom
encod
two
nonstructur
nine
structur
protein
includ
f
fusion
g
attach
glycoprotein
viral
envelop
antibodi
f
g
protein
neutral
shown
confer
protect
rsv
infect
anim
model
immun
primari
infect
gener
occur
year
age
partial
shortliv
thu
reinfect
occur
throughout
life
low
serum
neutral
antibodi
level
adult
predict
infect
risk
diseas
sever
immunolog
mechan
eg
cytokin
respons
implic
pathogenesi
sever
rsv
diseas
howev
emerg
evid
suggest
uncontrol
viral
replic
indic
high
respiratori
tract
viral
load
drive
diseas
manifest
associ
sever
clinic
outcom
find
provid
import
rational
approach
antivir
drug
develop
rsv
epidemiolog
rsv
known
import
caus
lower
respiratori
tract
infect
infant
young
children
eg
acut
bronchiol
wheezi
attack
result
hospit
death
adult
estim
rsv
infect
popul
prevent
vaccin
chemoprophylaxi
avail
coronavirus
present
droplet
contact
precaut
includ
use
face
mask
advis
prevent
transmiss
transmiss
could
opportunist
airborn
appropri
isol
precaut
negativepressur
facil
avail
implement
hospit
patient
confirm
novel
coronaviru
infect
particularli
respiratori
procedur
devic
appli
diagnost
microbiolog
high
index
suspicion
togeth
detail
clinic
epidemiolog
assess
eg
travel
histori
affect
area
case
cluster
requir
diagnosi
novel
coronaviru
infect
rtpcr
diagnost
test
choic
combin
upper
respiratori
nasal
pharyng
nasopharyng
lower
respiratori
higher
yield
due
higher
viral
level
eg
sputum
tracheal
aspir
bronchoalveolar
lavag
bal
whenev
avail
blood
fecal
sampl
repeat
sampl
consid
maxim
chanc
viru
detect
singl
neg
test
upper
respiratori
sampl
may
insuffici
rule
diagnosi
sarscov
plasma
rtpcr
detect
viremia
earli
day
symptom
onset
level
may
prognost
valu
viru
cultur
eg
use
vero
cell
confirmatori
delay
result
prevent
use
clinic
manag
also
biosafeti
facil
requir
serolog
diagnosi
retrospect
larg
use
epidemiolog
surveil
purpos
clinician
refer
local
refer
laboratori
coronaviru
test
eg
pancoronaviru
rtpcr
specif
sarscov
merscov
rtpcr
clinic
manifest
incub
period
sar
day
rang
day
patient
initi
develop
fever
chill
rigor
partial
subsid
day
follow
resurg
high
fever
cough
short
breath
develop
pneumonia
chest
radiograph
first
reveal
patch
consolid
groundglass
chang
rapidli
progress
next
day
involv
multipl
lobe
ct
scan
thorax
may
show
featur
resembl
bronchiol
obliteran
organ
pneumonia
peripher
airspac
consolid
laboratori
featur
includ
lymphopenia
thrombocytopenia
elev
transaminas
creatinin
kinas
lactat
dehydrogenas
around
day
patient
deterior
develop
refractori
respiratori
failur
ard
patient
develop
profus
diarrhea
contain
highli
infecti
viru
particl
renal
failur
rare
complic
includ
ventilatorassoci
pneumonia
eg
mrsa
pneumothorax
pneumomediastinum
overal
death
rate
sar
agestratifi
case
fatal
rate
year
year
year
year
young
children
eg
year
typic
mild
diseas
fatal
rare
avail
data
indic
clinic
featur
merscov
similar
sar
patient
develop
high
fever
chill
cough
short
breath
progress
pneumonia
week
symptom
onset
imag
find
includ
multipl
patchi
consolid
groundglass
chang
addit
lymphopenia
thrombocytopenia
elev
liver
enzym
acut
renal
failur
seem
common
featur
major
adult
patient
sever
infect
older
mean
age
year
underli
condit
eg
diabet
mellitu
renal
impair
requir
icu
care
respiratori
failur
ard
associ
fatal
rate
patient
rate
high
despit
maxim
medic
support
notabl
affect
children
usual
mild
symptom
case
sar
manag
present
establish
therapi
coronaviru
infect
sar
outbreak
rang
agent
use
b
consolid
groundglass
opac
typic
small
patchi
unilater
major
adult
hospit
rsv
develop
sever
lower
respiratori
complic
includ
pneumonia
acut
bronchiti
exacerb
copd
asthma
result
respiratori
failur
hypoxemia
develop
cardiovascular
complic
congest
heart
failur
acut
coronari
syndrom
bacteri
superinfect
occur
least
publish
data
suggest
around
patient
requir
ventilatori
support
respiratori
failur
overal
mortal
approxim
outcom
gener
compar
season
influenza
present
establish
antivir
therapi
vaccin
avail
rsv
ribavirin
vitro
activ
rsv
anim
model
palivizumab
rsvspecif
monoclon
antibodi
direct
f
glycoprotein
shown
reduc
viral
titer
replic
pulmonari
tissu
random
clinic
trial
palivizumab
given
prophylact
young
highrisk
children
shown
reduc
hospit
relat
rsv
infect
immunocompromis
adult
ribavirin
aerosol
system
administr
palivizumab
use
treat
rsv
infect
aim
reduc
progress
lower
respiratori
diseas
death
variabl
result
lack
control
data
known
whether
approach
appli
older
nonimmunocompromis
adult
new
antivir
agent
eg
fusion
protein
polymeras
inhibitor
sirna
newer
gener
antibodi
therapi
activ
research
system
corticosteroid
commonli
use
treat
wheez
exacerb
copdasthma
adult
includ
trigger
viral
infect
random
control
trial
corticosteroid
therapi
young
children
rsv
infect
reveal
lack
clinic
benefit
inconsist
control
inflammatori
cytokin
respons
recent
studi
corticosteroid
adult
report
viru
control
seem
unaffect
humor
immun
rsv
diminish
suggest
decis
treat
rsv
patient
corticosteroid
weigh
potenti
risk
eg
bacteri
superinfect
limit
short
cours
use
high
rate
secondari
infect
prudent
test
treat
bacteri
pathogen
accord
local
resist
profil
addit
streptococcu
pneumonia
haemophilu
influenza
pseudomona
aeruginosa
gramneg
bacilli
annual
although
infect
mild
sever
lower
respiratori
tract
infect
occur
especi
among
older
adult
eg
year
underli
condit
eg
chronic
lung
diseas
chronic
cardiovascular
diseas
rsv
shown
account
communityacquir
pneumonia
hospit
admiss
acut
cardiorespiratori
diseas
excess
death
among
adult
season
peak
outbreak
among
nurs
home
resid
common
underrecogn
diseas
burden
rsv
shown
approach
season
influenza
patient
profoundli
immunosuppress
hematopoiet
stem
cell
transplant
hsct
recipi
particularli
high
risk
sever
rsv
infect
rapidli
fatal
diagnost
microbiolog
rsv
infect
clinic
indistinguish
viral
respiratori
infect
diagnosi
requir
laboratori
test
upper
respiratori
tract
specimen
eg
nasal
throat
nasopharyng
commonli
use
lower
respiratori
sampl
eg
tracheal
aspir
bal
consid
whenev
avail
gold
standard
diagnosi
rtpcr
test
antigen
assay
eg
enzym
immunoassay
cultur
much
lower
sensit
see
figur
especi
among
adult
lower
viral
load
neg
antigen
assay
result
use
rule
rsv
infect
serolog
detect
rsvspecif
igg
antibodi
may
also
assist
diagnosi
avail
use
combin
rtpcr
maxim
yield
clinic
manifest
rsv
infect
infant
young
children
lead
sever
lower
respiratori
tract
ill
pneumonia
bronchiol
clinic
manifest
rsv
infect
adult
divers
often
determin
underli
condit
eg
chronic
lung
diseas
degre
immunosuppress
healthi
young
adult
rsv
may
caus
selflimit
upper
respiratori
ill
profoundli
immunosuppress
progress
pneumon
occur
result
high
mortal
older
adult
hospit
rsv
infect
may
present
fever
cough
sputum
product
wheez
dyspnea
although
wheez
dyspnea
may
common
rsv
magnitud
fever
sometim
lower
find
could
reliabl
differenti
influenza
radiograph
case
show
activ
pneumon
chang
blood
vessel
transud
plasma
increas
glandular
secret
togeth
result
local
congest
trigger
sneez
cough
reflex
immun
typespecif
shortliv
result
eventu
clearanc
viru
local
major
replic
initi
felt
limit
upper
airway
grow
bodi
evid
suggest
hrv
frequent
may
replic
lower
airway
like
common
among
individu
lower
airway
sign
symptom
may
contribut
pneumonia
may
occur
rare
immunocompromis
adult
children
lower
airway
involv
may
contribut
asthma
copd
exacerb
prevent
current
avail
vaccin
hrv
cornerston
transmiss
dilig
hand
hygien
symptomat
adult
advis
wash
hand
frequent
use
dispos
tissu
current
droplet
precaut
recommend
prevent
nosocomi
transmiss
rhinovir
infect
hrv
grown
cell
cultur
molecular
diagnost
sensit
current
wide
avail
typic
cytopath
effect
seen
hrv
grown
human
embryon
kidney
human
fibroblast
cell
line
includ
human
foreskin
fibroblast
hff
hela
see
figur
hrv
acid
labil
allow
differenti
enterovirus
preferenti
grow
ph
molecular
assay
target
region
highli
conserv
among
hrv
enterovirus
result
molecular
assay
detect
differenti
hrv
enterovirus
although
newer
diagnost
platform
circumv
problem
common
manifest
hrv
infect
includ
common
cold
exacerb
asthma
copd
although
seriou
infect
includ
pneumonia
describ
particularli
immunocompromis
adult
children
follow
typic
incub
period
patient
cold
develop
wateri
rhinorrhea
nasal
congest
sneez
cough
sore
throat
headach
sometim
fever
last
day
rhinovir
cold
differenti
caus
pathogen
primari
viral
may
need
consid
patient
underli
chronic
lung
diseas
rhinoviru
natur
human
rhinovirus
hrv
member
famili
picornavirida
genu
enteroviru
hrv
positivesens
singlestrandedrna
virus
encod
singl
protein
cleav
viral
mediat
proteas
protein
make
viral
capsid
well
serotyp
gener
phylogenet
organ
three
differ
speci
hrva
serotyp
hrvb
serotyp
recent
identifi
hrvc
serotyp
identifi
date
epidemiolog
hrv
infect
occur
worldwid
peak
incid
earli
fall
spring
temper
climat
although
infect
occur
year
round
hrvc
peak
incid
fall
winter
temper
region
raini
season
tropic
region
infect
occur
age
group
hrv
respons
half
common
cold
increasingli
associ
sever
upper
lower
respiratori
tract
infect
children
elderli
immunocompromis
hrv
transmit
person
person
via
contact
either
direct
fomit
aerosol
small
larg
particl
hrv
surviv
hour
long
day
nonpor
surfac
hour
human
skin
major
hrv
bind
intercellular
adhes
molecul
wherea
minor
group
hrv
adher
lowdens
lipoprotein
receptor
ldlr
heparan
sulfat
also
demonstr
addit
receptor
hrv
follow
infect
respiratori
epithelium
signific
inflammatori
cytokin
includ
rant
epitheli
cellderiv
neutrophilactiv
peptid
bradykinin
prostaglandin
histamin
releas
local
turn
result
vasodil
nasal
upper
airway
ciliat
epitheli
cell
infect
spread
larg
small
airway
peak
symptom
correl
peak
viral
replic
infect
larynx
upper
trachea
associ
croup
wherea
bronchiol
pneumonia
associ
infect
distal
airway
host
immun
respons
appear
play
import
role
pathogenesi
piv
infect
direct
viral
replic
specif
key
host
immun
respons
contribut
viral
clearanc
includ
innat
immun
respons
tcell
respons
interferon
product
local
system
iga
ige
igg
respons
also
key
driver
clinic
sign
symptom
infect
humor
cellular
immun
respons
critic
clearanc
infect
defect
cytotox
tcell
respons
associ
progress
diseas
demonstr
increas
risk
progress
fatal
diseas
hsct
recipi
current
licens
vaccin
piv
although
sever
candid
appear
produc
neutral
antibodi
hn
f
protein
investig
contemporari
vaccin
candid
focus
revers
genet
technolog
appli
live
attenu
intranas
vaccin
candid
vaccin
afford
protect
piv
rsv
nosocomi
outbreak
piv
infect
document
highlight
import
standard
contact
precaut
use
privat
room
whenev
possibl
respiratori
precaut
necessari
droplet
larg
aerosol
piv
diagnos
cultur
antigen
detect
nucleic
acid
test
piv
stabl
viral
transport
medium
day
freez
decreas
infect
viru
longterm
storag
achiev
easili
ad
sucros
glycerol
hold
media
freez
less
rhesu
monkey
kidney
vero
african
green
monkey
kidney
human
lung
carcinoma
cell
line
use
standard
shell
vial
techniqu
use
cultur
piv
fixedmix
cell
line
rmix
diagnost
hybrid
athen
oh
sensit
approach
standard
cell
cultur
line
detect
piv
trypsin
requir
growth
hemadsorptioninhibit
hemagglutin
inhibit
immunofluoresc
use
identifi
piv
cultur
see
current
approv
rapid
antigen
kit
avail
detect
piv
although
monoclon
antibodi
use
detect
piv
serotyp
primari
patient
sampl
cell
cultur
polymeras
chain
reaction
pcr
base
test
typic
direct
toward
hemagglutininneuraminidas
hn
gene
consid
gold
standard
diagnosi
piv
assay
typic
higher
yield
cultur
diagnosi
piv
despit
advantag
highli
multiplex
pcrbase
system
detect
wide
rang
virus
diagnost
yield
piv
consist
avail
system
parainfluenza
virus
caus
varieti
upper
lower
respiratori
tract
ill
rang
mild
coldlik
syndrom
lifethreaten
pneumonia
infect
children
limit
upper
respiratori
tract
involv
lower
respiratori
tract
upper
tract
diseas
may
involv
entir
airway
includ
middl
ear
sinus
associ
croup
laryngotracheobronch
children
character
fever
rhinorrhea
pharyng
typic
follow
bark
cough
otiti
rhinosinus
may
also
occur
hrv
typic
occur
earlier
bacteri
superinfect
occur
later
cours
cold
lower
airway
infect
includ
croup
bronchiol
pneumonia
describ
hrv
common
trigger
exacerb
asthma
copd
may
caus
direct
infect
lower
airway
stimul
inflammatori
immunolog
neurogen
mechan
manag
number
small
molecul
antivir
capsidbind
agent
pleconaril
vapendavir
pirodavir
proteas
inhibitor
rupintrivir
solubl
tremacamra
complementari
medic
intervent
echinacea
zinc
studi
treatment
rhinovir
cold
none
approv
use
interferon
shown
prevent
hrv
cold
document
posit
therapeut
effect
result
mainstay
treatment
rhinovir
cold
remain
symptomat
treatment
analges
agent
decongest
antihistamin
antituss
parainfluenza
viru
natur
parainfluenza
virus
piv
singlestrand
envelop
rna
virus
belong
genu
paramyxoviru
paramyxovirida
famili
singl
strand
negativesens
rna
encod
least
six
viral
protein
nucleocapsid
protein
np
phosphoprotein
p
matrix
protein
fusion
glycoprotein
f
hemagglutininneuraminidas
glycoprotein
hn
rna
polymeras
l
four
major
serotyp
human
piv
defin
complement
fixat
hemagglutin
antigen
initi
infect
parainfluenza
typic
occur
earli
childhood
commonli
children
less
year
old
serolog
studi
demonstr
affect
children
within
first
year
life
caus
initi
infect
later
gener
year
old
adult
antibodi
piv
piv
respons
lower
respiratori
tract
infect
second
common
viral
caus
hospit
children
contemporari
molecular
diagnost
piv
also
demonstr
second
third
commonli
isol
viru
hospit
adult
age
year
old
adult
children
reinfect
common
despit
presenc
antibodi
form
prior
infect
tropic
subtrop
region
parainfluenza
virus
show
season
variat
temper
region
usa
caus
season
outbreak
fall
septemberdecemb
caus
epidem
spring
apriljun
year
circul
typic
evennumb
year
activ
gener
greater
gener
caus
milder
degre
ill
common
autumn
winter
month
parainfluenza
one
common
caus
respiratori
viral
infect
patient
hematolog
malign
hematopoiet
stem
cell
transplant
solid
organ
transplant
associ
high
rate
progress
diseas
involv
lower
airway
increas
mortal
rate
pathogen
parainfluenza
virus
transmit
direct
persontoperson
contact
larg
respiratori
droplet
contact
fomit
contamin
respiratori
secret
clinic
symptom
typic
develop
day
incub
period
initi
infect
associ
distal
lung
involv
particularli
first
month
life
gener
associ
mild
upper
respiratori
infect
asymptomat
infect
although
sever
diseas
describ
children
underli
cardiopulmonari
diseas
immun
compromis
nonrespiratori
complic
piv
includ
mening
myocard
pericard
syndrom
adult
diseas
piv
respons
acut
typic
mild
respiratori
ill
adult
higher
rate
signific
morbid
older
adult
higher
rate
pneumonia
describ
elderli
wider
use
sensit
molecular
assay
demonstr
piv
signific
caus
communityacquir
pneumonia
exacerb
asthma
chronic
bronchiti
parainfluenza
viru
caus
signific
direct
indirect
morbid
mortal
among
immunocompromis
adult
children
piv
caus
asymptomat
shed
particularli
among
hsct
describ
frequent
among
immunocompromis
patient
elderli
children
infect
year
age
hmpv
second
frequent
isol
viral
pathogen
rsv
children
present
bronchiol
infect
typic
occur
late
winter
spring
temper
climat
spring
summer
subtrop
region
epidem
peak
typic
occur
month
later
rsv
epidem
annual
pathogen
hmpv
like
transmit
direct
close
contact
contamin
secret
larg
particl
aerosol
droplet
fomit
may
also
result
transmiss
typic
interv
onset
symptom
index
case
onset
symptom
household
expos
contact
hmpv
g
protein
bind
integrin
receptor
respiratori
epitheli
cell
local
replic
airway
associ
upper
respiratori
tract
sign
signific
airway
inflamm
viral
replic
also
induc
mucu
hyperproduct
hyperplasia
respiratori
epithelium
may
result
airway
obstruct
hyperrespons
methacholin
challeng
replic
result
increas
tumor
necrosi
factor
although
level
lower
observ
rsv
infect
current
licens
vaccin
hmpv
although
sever
current
investig
candid
vaccin
util
chimer
virus
liveattenu
virus
subunit
viru
nosocomi
outbreak
describ
highlight
import
droplet
contact
precaut
prevent
transmiss
although
hmpv
may
grown
tertiari
monkey
kidney
cell
vero
cell
cell
cell
cell
yield
often
low
requir
prolong
incub
cytopath
effect
typic
observ
day
rang
syncytia
format
round
cell
direct
immunofluoresc
assay
dfa
virusspecif
antibodi
avail
allow
detect
viru
direct
patient
specimen
cell
cultur
dfa
less
sensit
pcr
often
wide
avail
molecular
diagnost
either
singleplex
multiplex
assay
commerci
avail
highest
yield
detect
hmpv
pcr
assay
detect
hmpv
genotyp
reli
conserv
essenti
region
within
n
f
l
gene
sensit
vari
assay
lower
multiplex
assay
compar
singleplex
assay
serolog
diagnosi
made
elisa
method
wide
avail
clinic
manifest
hmpv
associ
respiratori
tract
infect
age
group
among
children
common
symptom
rhinorrhea
cough
fever
although
conjunct
vomit
diarrhea
rash
report
infrequ
enceph
rare
manifest
hmpv
infect
although
hmpv
rsv
gener
indistinguish
fever
frequent
children
hmpv
rhinorrhea
commonli
observ
rsvinfect
individu
children
appear
higher
risk
develop
bronchiol
pneumonia
croup
possibl
asthma
exacerb
particularli
younger
year
age
hospit
result
bronchiol
pneumonia
children
coinfect
hmpv
rsv
result
sever
diseas
increas
risk
admiss
icu
increas
need
mechan
ventil
typic
durat
symptom
around
week
viral
shed
typic
week
repeat
infect
clearli
document
although
subsequ
infect
typic
limit
recipi
may
contribut
nosocomi
spread
progress
lower
respiratori
tract
complic
case
associ
enhanc
mortal
rare
lower
airway
involv
character
small
peribronchi
nodul
ct
radiographi
steroid
dose
depend
manner
associ
increas
risk
progress
upper
lower
tract
diseas
mortal
risk
factor
progress
diseas
includ
onset
earli
posttranspl
allogen
match
unrel
match
relat
donor
presenc
lymphocytopenia
activ
graftversushost
diseas
pediatr
age
group
reduc
intens
condit
appear
risk
factor
late
onset
day
piv
infect
piv
infect
associ
greater
odd
develop
sever
airflow
declin
follow
infect
parainfluenza
also
demonstr
caus
sever
diseas
patient
undergo
chemotherapi
enhanc
risk
progress
sever
lower
respiratori
infect
patient
sever
lymphocytopenia
parainfluenza
viru
infect
among
lung
transplant
recipi
associ
signific
shortand
longterm
pulmonari
dysfunct
addit
local
acut
direct
virolog
effect
lung
transplant
recipi
piv
particularli
lower
tract
infect
associ
develop
progress
bronchiol
obliteran
bronchiol
obliteran
syndrom
bo
current
antivir
proven
efficaci
approv
treatment
piv
infect
children
croup
glucocorticoid
nebul
epinephrin
associ
improv
clinic
outcom
approv
antivir
ribavirin
studi
typic
immunocompromis
patient
treatment
associ
reduct
viral
shed
mortal
one
investig
agent
act
cleav
sialic
acid
receptor
surfac
human
respiratori
epitheli
cell
shown
improv
symptom
oxygen
pulmonari
function
nasopharyng
viral
load
treat
subject
piv
infect
human
metapneumoviru
natur
human
metapneumoviru
hmpv
nonseg
negativesens
rna
viru
member
pneumovirina
subfamili
paramyxovirida
two
subgroup
two
clade
hmpv
although
four
subtyp
typic
cocircul
season
often
one
subtyp
predomin
hmpv
code
similar
gene
rsv
except
order
slightli
differ
gene
epidemiolog
hmpv
result
typic
selflimit
upper
lower
respiratori
tract
infect
age
group
global
distribut
symptomat
diseas
appear
common
among
young
children
elderli
risk
factor
hospit
hmpv
infect
children
includ
age
month
presenc
three
children
home
wherea
femal
gender
prematur
genotyp
b
infect
risk
factor
sever
diseas
children
requir
hospit
sever
respiratori
symptom
pneumonia
hmpv
identifi
adult
hospit
acut
cardiorespiratori
ill
risk
factor
hospit
sever
diseas
elderli
includ
diagnosi
copd
asthma
cancer
lung
transplant
averag
rate
hospit
hmpv
per
resid
similar
rate
influenza
per
resid
adult
year
old
sever
sometim
fatal
infect
includ
pneumonia
infect
immunocompet
individu
studi
wheez
children
serolog
evid
primari
infect
sever
studi
includ
asymptomat
control
patient
document
associ
presenc
hbov
clinic
symptom
addit
studi
document
posit
correl
high
copi
number
dna
monoinfect
respiratori
symptom
although
exact
rout
transmiss
human
bocavirus
unknown
transmiss
inhal
contact
infecti
sputum
fece
urin
probabl
mechan
cell
entri
host
rang
known
although
detect
upper
airway
clinic
symptom
posit
bal
specimen
suggest
capabl
infect
lower
airway
least
bronchiol
dna
detect
serum
suggest
dissemin
beyond
airway
likewis
rare
detect
stool
without
gastrointestin
symptom
suggest
passiv
spread
respiratori
gastrointestin
tract
vitro
induc
cell
children
bronchiol
increas
level
nasopharyng
aspir
prevent
vaccin
avail
hbov
specialist
advic
sought
regard
appropri
isol
practic
patient
proven
hbov
infect
diagnosi
hbov
depend
molecular
serolog
method
hbov
cultur
differenti
human
airway
epitheli
cell
wide
avail
clinic
microbiolog
laboratori
pcr
optim
diagnost
method
prolong
shed
potenti
persist
infect
tissu
presenc
dna
serum
may
provid
enhanc
specif
activ
infect
correl
igm
time
quantit
virolog
may
also
help
improv
probabl
hbov
detect
associ
clinic
present
high
viral
load
genomesml
nasopharyng
aspir
appear
correl
ill
sever
fewer
coinfect
serolog
particularli
igg
avid
eia
may
also
increas
probabl
detect
hbov
truli
associ
clinic
diseas
given
limit
diagnost
strategi
would
recommend
use
two
diagnost
modal
diagnos
hbov
infect
limit
outlin
remain
controversi
causal
link
respiratori
diseas
number
studi
correl
detect
common
cold
asthma
acut
wheez
bronchiol
pneumonia
acut
otiti
media
plastic
bronchiti
strongest
link
avail
literatur
may
caus
wheez
pneumonia
one
studi
found
link
dna
serum
cerebrospin
fluid
csf
stool
kawasaki
diseas
although
studi
confirm
two
group
manag
compar
studi
avail
antivir
conduct
patient
hbov
infect
support
measur
current
avail
therapi
refer
avail
onlin
expertconsultcom
upper
airway
sever
sometim
fatal
infect
often
involv
lower
airway
describ
adult
children
malign
hematopoiet
stem
cell
solid
organ
transplant
sever
ill
like
relat
reduc
cellular
immun
respons
likewis
elderli
adult
adult
sever
cardiopulmonari
diseas
resid
longterm
care
facil
higher
incid
hmpv
infect
increas
risk
lower
airway
involv
complic
includ
bacteri
superinfect
death
although
asymptomat
infect
common
otherwis
healthi
adult
individu
may
present
coldand
influenzalik
ill
adult
commonli
present
cough
nasal
congest
rhinorrhea
rare
fever
role
hmpv
exacerb
copd
unclear
one
larg
studi
demonstr
associ
wherea
anoth
fail
identifi
hmpv
patient
copd
exacerb
manag
gener
patient
safe
manag
support
care
includ
supplement
oxygen
intraven
hydrat
indic
bronchodil
corticosteroid
often
use
empir
although
control
trial
medic
hmpv
ribavirin
show
equival
activ
hmpv
mean
rsv
mean
likewis
standard
igiv
neutral
antibodi
hmpv
log
rsv
log
wherea
rsvspecif
monoclon
antibodi
activ
hmpv
neither
agent
studi
prospect
treatment
hmpv
although
number
case
seri
demonstr
clinic
respons
case
human
bocaviru
natur
human
bocavirus
first
identifi
molecular
screen
bocavirus
nonenvelop
linear
singlestrand
dna
virus
member
parvovirida
famili
current
four
speci
human
bocavirus
divid
two
strain
b
viral
genom
encod
two
form
nonstructur
protein
nuclear
phosphoprotein
two
major
structur
protein
epidemiolog
human
bocavirus
detect
worldwid
respiratori
stool
specimen
predominantli
respiratori
pathogen
wherea
mostli
found
stool
less
clearli
associ
respiratori
tract
infect
although
commonli
detect
children
month
old
detect
less
frequent
age
group
infect
appear
occur
year
round
peak
detect
winter
spring
although
felt
predominantli
gastrointestin
virus
detect
nasopharyng
specimen
children
antibodi
age
adult
detect
antibodi
key
challeng
understand
pathogenesi
clinic
implic
hbov
fact
hbov
dnaposit
respiratori
sampl
evid
coinfect
respiratori
virus
viru
often
shed
least
month
initi
